Monday, March 13, 2017 | 9:00 AM - 5:00 PM
Speakers: Michael G. Agadjanyan (The Institute for Molecular Medicine), Bernardino Ghetti (Indiana University School of Medicine), Khalid Iqbal (New York State Institute for Basic Research in Developmental Disabilities), Viktoriya Morozova (College of Staten Island, The City University of New York), Andreas Muhs AC Immune SA), Einar M. Sigurdsson (New York University School of Medicine), Qian Wu (New York University School of Medicine), and Henrik Zetterberg (University of Gothenburg, Sweden)
This event will cover the translational potential of immunotherapy for tauopathies, reviewing the pre-clinical and clinical development of several tau immunotherapy programs that exemplify this emerging therapeutic approach.
Tuesday, March 21, 2017 | 12:00 PM - 5:00 PM
Speakers: Tsuneya Ikezu (Boston University School of Medicine), David Issadore (University of Pennsylvania), Xandra Breakefield (Massachusetts General Hospital), Efrat Levy (NYU School of Medicine), Robert A. Rissman (University of California San Diego, School of Medicine), and Andrew West (The University of Alabama at Birmingham)
In this symposium we will explore the contribution of extracellular vesicles to pathological processes underlying neurodegenerative disorders, and the appeal of exosomes as biomarkers and targets for the development of novel therapeutics.
Tuesday, April 11, 2017 | 9:00 AM - 5:00 PM
Speakers: Brian Kaspar (Nationwide Children's Hospital), R. Jude Samulski (Bamboo Therapeutics), Barry Byrne (University of Florida, Powell Gene Therapy Center), Maria Escolar (Children's Hospital of Pittsburgh), Jakub Tolar (University of Minnesota), Kevin Flanigan (Nationwide Children's Hospital), Katherine A. High (Spark Therapeutics), and David Pearce (Sanford Research)
Gene therapy has been proposed as a promising therapeutic strategy for monogenic disorders. This symposium will explore recent advances in the field, and identify ongoing obstacles on the path to wider use of this approach.
May 15 - 17, 2017
Keynote Speaker: Vijay K. Kuchroo (Harvard Institutes of Medicine)
Learn about most recent advances in basic, translational, and clinical research on the rare, acquired disorder, Myasthenia Gravis, as well as implications of this research on a range of related autoimmune and neuromuscular diseases.
Wednesday, May 24, 2017 | 12:00 PM - 5:00 PM
Speakers: Sean F. Brady (The Rockefeller University), Dirk Trauner (New York University)
The Chemical Biology Discussion Group brings together chemists and biologists interested in discussing the latest breakthroughs. In 2017, the annual year-end meeting features keynote speakers Dr Sean F. Brady and Dr Dirk Trauner.
Tuesday, December 6, 2016 | 9:00 AM - 5:00 PM
Speakers: Katerina Akassoglou (University of California, San Francisco), Robert Dempsey (University of Wisconsin), Paula Grammas (University of Rhode Island), Steven Greenberg (Massachusetts General Hospital and Harvard Medical School), Jaime Grutzendler (Yale University), Costantino Iadecola (Weill Cornell Medicine), Jeffrey Iliff (Oregon Health & Science University), Berislav Zlokovic (Keck School of Medicine of USC), Heather Snyder (Alzheimer's Association), Zorina Galis (NIH)
This symposium will highlight basic research and clinical science elucidating the mechanisms underlying the contribution of inflammatory pathways to vascular cognitive impairment and dementia (VCID).
Tuesday, October 25, 2016 | 9:00 AM - 5:00 PM
Speakers: Marcus Bantscheff (Cellzome/GSK), Benjamin F Cravatt (The Scripps Research Institute), Craig Crews (Yale University), Howard Hang (The Rockefeller University), Ruth Nussinov (National Cancer Institute), Brian Raymer (Pfizer), Bryan Roth (University of North Carolina), Eranthie Weerapana (Boston College)
Chemical Biology is changing the face of drug discovery. This symposium will highlight recent developments in the field, featuring examples from neurobiology and cancer, the ubiquitin proteasome system, GPCRs, and protein lipidation.
Wednesday, July 13, 2016 | 9:00 AM - 5:00 PM
Keynote Speaker: David Bartel (Whitehead/MIT/HHMI)
Speakers: Paul Grint (Regulus Therapeutics), David S Hong (The University of Texas MD Anderson Cancer Center ), Daniel J Siegwart (University of Texas Southwestern Medical Center), Frank Slack (BIDMC Cancer Center/Harvard Medical School), James W Welsh (The University of Texas MD Anderson Cancer Center)
miRNAs play critical roles in regulating gene expression. This symposium will present up-to-date basic, translational, and clinical research addressing the biology of miRNA and their promise as a therapeutic target.
Tuesday, June 28, 2016 | 8:00 AM - 5:30 PM
Keynote Speaker: Giancarlo Comi (Università Vita-Salute San Raffaele)
Explore novel and emerging treatments for multiple sclerosis, including biomarkers and MRI usage in disease diagnosis, prognosis, and monitoring.
Keynote Speakers: Barry G. Arnason, MD (University of Chicago) and Giancarlo Comi, MD (Università Vita-Salute San Raffaele)
This one-day, translational conference brought together academic and clinical researchers with industry leaders to discuss current therapeutics.
Keynote Speaker: David Bartel (Whitehead Institute for Biomedical Research, Howard Hughes Medical Institute, MIT)
MicroRNAs (miRNA) play critical roles in regulating gene expression. This symposium presented up-to-date basic, translational, and clinical research addressing the biology of miRNA and their promise as a therapeutic target.
Edited by Annals of the New York Academy of Sciences
This diverse collection of papers discusses topics ranging from a paleobiologic study of the emergence of the diaphragm to changes in gait patterns after acute brain injury.
Featuring: Sharon Inouye (Harvard Medical School)
Surgery helps millions of Americans overcome illness to live longer, healthier lives. Yet surgery can lead to delirium, cognitive decline, and perhaps even a higher long-term risk of dementia for many patients, a risk that is poorly understood and often under-recognized in the clinic. With numerous factors—including age—contributing to each patient's level of risk, what are the challenges and opportunities to creating biomarkers and therapeutics for those who are most vulnerable?